Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Condition: Neoplasms
Intervention: BIBW 2992
Intervention description: patients to receive continuous oral daily dosing of BIBW 2992
Intervention MeSH terms: Afatinib
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 60.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the
      effectiveness of afatinib (BIBW 2992) in treating certain cancers. Cancers studied will
      include glioblastoma and cancers which have spread to the brain (metastases).
    

Eligibility criteria:

        Inclusion criteria:

          1. Male or female patients aged at least 18 years old.

          2. Histologically or cytologically confirmed diagnosis of a solid malignant tumour, known
             to express EGFR/HER2 that is either refractory to standard therapies, or for which no
             standard treatment is available (including patients with brain metastases).

          3. At least one tumor lesion that can accurately be measured by computed tomography (CT)
             or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to
             be recorded as greater than or equal to 20 mm using conventional techniques or greater
             than or equal to 10 mm with spiral CT scan.

          4. Life expectancy of at least 3 months.

          5. Written informed consent that is consistent with ICH-GCP guidelines.

          6. Eastern Cooperative Oncology Group (ECOG) performance score 0,1 or 2.

          7. Patients must have recovered from any previous surgery.

          8. Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control) for the duration of trial participation.
             Female patients with reproductive potential must have a negative serum pregnancy test
             within 7 days of trial enrolment. Breast feeding mothers will be excluded since these
             agents may be toxic to infants.

        For patients with Glioma and brain metastases the following additional inclusion criteria
        should apply:

          1. Histologically-confirmed WHO Grade IV malignant glioma at first episode of recurrence
             after prior combined chemo-radiotherapy. Patients with prior low-grade glioma are
             eligible if histological assessment demonstrates transformation to WHO Grade IV
             malignant glioma.

          2. Bi-dimensionally measurable disease with a minimum measurement of 1 cm (10 mm) in one
             diameter on Gd MRI performed within 14 days prior to first treatment (Day 1).

        Exclusion criteria:

        Major exclusion criteria; 9. Radiotherapy within the past 2 weeks prior to treatment with
        the trial drug. 10. Chemo-, hormone- (other than megestrol acetate or steroids required for
        maintenance non-cancer therapy) or immunotherapy within the past 4 weeks before first drug
        administration.

        11. Patients not completely recovered from any therapy-related toxicities from previous
        chemo-, hormone-, immuno-, or radiotherapies to CTC < Grade 1. Prior chemotherapy is
        allowed if completed at least 4 weeks prior to first trial treatment (6 weeks for mitomycin
        C or nitrosoureas) and the patient has recovered from the acute toxicities of that therapy.

        12. Prior treatment with EGFR targeting therapies or treatment with EGFR- or HER2
        inhibiting drugs within the past four weeks before start of therapy or concomitantly with
        this trial.

        15. History of clinically significant or uncontrolled cardiac disease, including congestive
        heart failure, angina, myocardial infarction, arrhythmia, including New York Heart
        Association (NYHA) functional classification of 3.

        16. Cardiac left ventricular function with resting ejection fraction < 50% measured by
        multigated blood pool imaging of the heart (MUGA scan) or Echocardiogram.

        17. QTcF- interval > 470 ms at screening. 18. PR-interval > 230 ms at screening. 19.
        QRS-interval >120 ms at screening. 20. ST-segment and T/U-wave abnormalities at screening,
        as will be assessed by a cardiology specialist of a central lab.

        21. Absolute neutrophil count (ANC) < 1,500/mm3. 22. Platelet count < 100,000 / mm3. 23.
        Bilirubin > 1.5 mg / dl (>26 micro mol / L, SI unit equivalent). Aspartate amino
        transferase (AST) or alanine amino transferase (ALT) > or equal to three times the upper
        limit of normal (if related to liver metastases > five times the upper limit of normal).

        24. Serum creatinine > 1.5 times of the upper normal limit or calculated/measured
        creatinine clearance > or equal to 45 ml / min.

        25. Patients with known Interstitial Lung Disease (ILD) For Patients with glioma and brain
        metastases additional exclusion criteria apply;

          1. Patients with untreated or symptomatic brain metastases. Patients with treated,
             asymptomatic brain metastases are eligible if there has been no change in brain
             disease status for at least four (4) weeks, no history of cerebral oedema or bleeding
             in the past four (4) weeks. Steroids will be allowed. Anti-epileptic therapy will be
             allowed if no changes are anticipated within the initial 14 days of treatment
             (QTC-evaluation).

          2. Less than 4 weeks between radiotherapy and start of study treatment, unless new
             enhancing lesion outside of radiation field or radiologically progressive on two
             consecutive MRI scans at least four weeks apart or biopsy-proven recurrence.

          3. Less than two weeks from surgical resection (one week from prior stereotactic biopsy)
             or major surgical procedure.

          4. Less than two weeks after previous chemotherapy (6 weeks from nitrosureas).

          5. Less than four weeks from prior treatment with bevacizumab.

          6. Treatment with other investigational drugs; participation in another clinical study
             within the past 2 weeks before start of therapy or concomitantly with this study.